EmpowerPharm Inc. Announces First Patient Enrolled in a Phase II Study Evaluating Empower CBD™ for the Treatment of Social Anxiety Disorder

Syneos Health Recruits First Participant in the Multi-center U.S. Study

Burlington, ON – October 4th,  2022 – EmpowerPharm Inc a clinical-stage life sciences company focused on research and clinical development announced today that the first patient has been enrolled in their Company-sponsored Phase II clinical study. EmpowerPharm is the sponsor of EPI-CBD-001, study (NCT05600114) a Phase II clinical trial, is a randomized, double blind, parallel group, placebo-controlled study evaluating the efficacy, safety and tolerability of cannabidiol in patients with Social Anxiety Disorder. 
The Phase II study is expected to enroll 225 patients at 22 clinical centers in the United States.